Thus, this study explored that BYF, the effective prescription for treating COPD, maintains airway epithelial barrier function in COPD by enhancing autophagy through the regulation of SIRT1/AMPK/FOXO3 signaling, which provide the basis for clinical application. The gene discussed is SIRT1; the disease is chronic obstructive pulmonary disease.